📰 Accelerated Plan News
Accelerated Plan News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Accelerated Plan. Real-time updates on events, politics, business and more.
November 16, 2023
Sigma Lithium Corp (TSX-V:SGML, NASDAQ:SGML) told investors it achieved positive operating profit as it reported its first results since it started...
November 15, 2023
SAO PAOLO, Nov. 14, 2023 SIGMA Lithium Corp. , a leading global lithium producer dedicated to powering the next generation of electric vehicles with carbon neutral, responsibly sourced chemical grade lithium concentrate, today announced its results... - Veroeffentlicht am 15.11.2023
November 15, 2023
Real-Time News, Market Data and Stock Quotes For Junior Mining Stocks.
November 2, 2023
Real-Time News, Market Data and Stock Quotes For Junior Mining Stocks.
November 1, 2023
MINERAL RESOURCE EXPLORATION PROGRAM UPDATE Sigma announces positive results from its Exploration Program of Phase 4. Expected to represent an approximate 25% potential increase of mineral resource...
January 30, 2023
No less than 12 funding programmes, totalling around EUR 5 billion, are available to companies and local public authorities in the coming months
September 13, 2022
The revision of NLEM 2022 has been done after constant consultation with stakeholders spanning from academia, industrialists and public policy experts etc., and crucial documents like WHO EML 2021.
September 13, 2022
The revision of NLEM 2022 has been done after constant consultation with stakeholders spanning from academia, industrialists and public policy experts etc., and crucial documents like WHO EML 2021.
September 13, 2022
A total of 384 drugs have been included in the National Lists of Essential Medicines (NLEM) 2022, which was released by the Union Health Minister Mansukh Mandaviya here on Tuesday. The list has got the addition of 34 new drugs, while 26 from ...
September 13, 2022
NLEM 2022: Covid drugs and vaccines have not been added to the list as they have been granted emergency use authorisations and the data is still not conclusive and complete from the regulatory perspective.